By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Artiva Biotherapeutics, Inc. (ARTV)

NASDAQ Currency in USD
$2.66
-$0.04
-1.48%
Last Update: 11 Sept 2025, 20:00
$64.97M
Market Cap
-0.82
P/E Ratio (TTM)
Forward Dividend Yield
$1.47 - $17.31
52 Week Range

ARTV Stock Price Chart

Explore Artiva Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ARTV price movements and trends.

ARTV Company Profile

Discover essential business fundamentals and corporate details for Artiva Biotherapeutics, Inc. (ARTV) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

Employees

96.00

CEO

Fred Aslan

Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

ARTV Financial Timeline

Browse a chronological timeline of Artiva Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 11 Nov 2025

EPS estimate is -$0.90.

Earnings released on 6 Aug 2025

EPS came in at -$0.87 falling short of the estimated -$0.84 by -3.57%.

Earnings released on 8 May 2025

EPS came in at -$0.83 falling short of the estimated -$0.68 by -22.06%.

Earnings released on 25 Mar 2025

EPS came in at -$0.66 surpassing the estimated -$0.71 by +7.04%.

Earnings released on 12 Nov 2024

EPS came in at -$0.92 falling short of the estimated -$0.68 by -35.29%.

Earnings released on 29 Aug 2024

EPS came in at -$22.00 falling short of the estimated -$4.40 by -400.00%, while revenue for the quarter reached $251.00K .

Earnings released on 30 Jun 2024

EPS came in at -$0.62 .

Earnings released on 31 Dec 2023

EPS came in at -$0.30 , while revenue for the quarter reached $33.49M .

Earnings released on 30 Sept 2023

EPS came in at $1.20 , while revenue for the quarter reached $26.66M .

Earnings released on 30 Jun 2023

EPS came in at -$0.90 .

Earnings released on 31 Mar 2023

EPS came in at -$0.95 , while revenue for the quarter reached $989.00K .

ARTV Stock Performance

Access detailed ARTV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run